Noë A J, Malapetsa A, Panasci L C
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montréal, Québec, Canada.
Mol Pharmacol. 1993 Jul;44(1):204-9.
The transport of (2-chloroethyl)-3-sarcosinamide-1-nitrosourea (SarCNU), an experimental anticancer compound, was investigated in the human glioma cell line SK-MG-1. The transport of [3H]SarCNU was examined in suspension. The uptake of [3H] SarCNU was found to be temperature dependent, with influx being linear to 4 sec at 37 degrees. Equilibrium was reached after 1 min at 22 degrees and 37 degrees, with accumulation slightly above unity. SarCNU was not significantly metabolized in the cells after a 60-min incubation at 37 degrees, as shown by thin layer chromatography. At 37 degrees, uptake of [3H]SarCNU was found to be saturable, sodium independent, and energy independent. Previous work demonstrated that SarCNU was able to inhibit the uptake of sarcosinamide, which is transported by the catecholamine uptake 2 system. This catecholamine system mediates the physiological transport of epinephrine. Epinephrine was able to significantly inhibit the uptake of [3H]SarCNU, at a concentration of 50 microM, by 40%. Additionally, several amino acids were unable to inhibit the uptake of SarCNU. The initial rate of SarCNU influx is mediated by both facilitated and nonfacilitated diffusion. The nonfacilitated diffusion rate could be estimated from the linear concentration dependence of the residual influx rate for SarCNU, which was not inhibited by the presence of excess co-permeant (epinephrine). Dixon plot analysis, corrected for nonfacilitated diffusion of SarCNU, revealed that epinephrine inhibited the uptake of SarCNU competitively, with a Ki of 163 +/- 15 microM, a value similar to the Km value for epinephrine influx in SK-MG-1 cells. Additionally, after appropriate corrections for nonfacilitated diffusion in the influx rates observed for SarCNU, it was revealed that SarCNU influx obeyed Michaelis-Menten kinetics over a 200-fold range of concentrations, with a Km of 2.39 +/- 0.37 mM and a Vmax of 236 +/- 53 pmol/microliters of intracellular water/sec. Metabolic poisons (2,4-dinitrophenol, iodoacetate, NaCN, NaF, or ouabain) were unable to inhibit the influx of SarCNU, suggesting that the carrier-mediated uptake of SarCNU is energy independent and mediated by facilitated diffusion. These findings indicate that SarCNU uptake in SK-MG-1 cells is mediated both by nonfacilitated diffusion and by facilitated diffusion via the catecholamine uptake 2 carrier system. SarCNU is the first chloroethylnitrosourea that has been demonstrated to have carrier-mediated uptake. Moreover, this carrier-mediated uptake may play a role in the increased cytotoxicity of SarCNU against gliomas, compared with that of 1,3-bis(2,-chloroethyl)-1-nitrosourea, which enters cells primarily by passive diffusion.
对一种实验性抗癌化合物(2-氯乙基)-3-肌氨酸酰胺-1-亚硝基脲(SarCNU)在人胶质瘤细胞系SK-MG-1中的转运进行了研究。在悬浮液中检测了[3H]SarCNU的转运。发现[3H]SarCNU的摄取具有温度依赖性,在37℃时,内流在4秒内呈线性。在22℃和37℃下1分钟后达到平衡,积累略高于1。如薄层色谱所示,在37℃孵育60分钟后,SarCNU在细胞内未发生明显代谢。在37℃时,发现[3H]SarCNU的摄取是可饱和的,不依赖钠且不依赖能量。先前的研究表明,SarCNU能够抑制肌氨酸酰胺的摄取,肌氨酸酰胺是由儿茶酚胺摄取2系统转运的。该儿茶酚胺系统介导肾上腺素的生理转运。肾上腺素能够在浓度为50 microM时显著抑制[3H]SarCNU的摄取,抑制率为40%。此外,几种氨基酸不能抑制SarCNU的摄取。SarCNU内流的初始速率由易化扩散和非易化扩散共同介导。非易化扩散速率可根据SarCNU残余内流速率的线性浓度依赖性来估计,过量共通透剂(肾上腺素)的存在不会抑制该速率。经校正SarCNU的非易化扩散后进行的Dixon图分析表明,肾上腺素竞争性抑制SarCNU的摄取,Ki为163±15 microM,该值与SK-MG-1细胞中肾上腺素内流的Km值相似。此外,在对SarCNU观察到的内流速率进行适当的非易化扩散校正后,发现SarCNU内流在200倍浓度范围内符合米氏动力学,Km为2.39±0.37 mM,Vmax为236±53 pmol/微升细胞内水/秒。代谢毒物(2,4-二硝基苯酚、碘乙酸、NaCN、NaF或哇巴因)不能抑制SarCNU的内流,这表明载体介导的SarCNU摄取不依赖能量,由易化扩散介导。这些发现表明,SK-MG-1细胞中SarCNU的摄取由非易化扩散和通过儿茶酚胺摄取2载体系统的易化扩散共同介导。SarCNU是首个被证明具有载体介导摄取的氯乙基亚硝基脲。此外,与主要通过被动扩散进入细胞的1,3-双(2-氯乙基)-1-亚硝基脲相比,这种载体介导的摄取可能在SarCNU对胶质瘤的细胞毒性增加中起作用。